

Klebsiella pneumoniae Infections Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

https://marketpublishers.com/r/KF4773F0EFF9EN.html

Date: October 2019

Pages: 100

Price: US\$ 1,699.00 (Single User License)

ID: KF4773F0EFF9EN

Abstracts

Klebsiella pneumoniae Infections Drug pipeline report- 2020 is an annual R&D review of Klebsiella pneumoniae Infections pipeline candidates. The report presents the current status of all major Klebsiella pneumoniae Infections therapeutic compounds. Detailed insights into Klebsiella pneumoniae Infections pipeline development, current status, companies, drug profiles and Klebsiella pneumoniae Infections preclinical and clinical trials are included.

2020 Klebsiella pneumoniae Infections Pipeline Market Insights
Klebsiella pneumoniae Infections disease overview, 2020 pipeline review, insights into
leading companies, dominant mechanism of action, majority of administration route of
Klebsiella pneumoniae Infections therapies, pipeline by phase and others are included.

Klebsiella pneumoniae Infections pipeline Drug profiles-

Active and inactive drug profiles covering information including drug name/synonym, sponsor/collaborators/Developer/originator, drug mechanism, route of administration, orphan drug status, NME, phase, development status, and others are included.

Klebsiella pneumoniae Infections Therapeutic Drug candidates
Both active and inactive Klebsiella pneumoniae Infections pipeline drug candidates are
included in the report

Klebsiella pneumoniae Infections Clinical Trials and preclinical Studies Klebsiella pneumoniae Infections In-vitro and In-vivo studies, discovery stage and pre-



clinical stage trial details, Clinical trial titles, duration, location, phase, sponsors, and other details are provided.

Klebsiella pneumoniae Infections pipeline market developments Klebsiella pneumoniae Infections Pipeline market news and deals including mergers, acquisitions, approvals, collaborations, trial initiations, results, investments, licensing opportunities and others are provided.

Klebsiella pneumoniae Infections pipeline companies in active development The report analyzes Klebsiella pneumoniae Infections pipeline of the below companies-

ABAC Therapeutics SA, Abgentis Ltd, AmpliPhi Biosciences Corp, Appili Therapeutics Inc, Armata Pharmaceuticals Inc, Biomx Ltd, C3J Therapeutics Inc, ContraFect Corp, Daiichi Sankyo Co Ltd, Debiopharm International SA, EnBiotix Inc, Evaxion Biotech ApS, F. Hoffmann-La Roche Ltd, Fedora Pharmaceuticals Inc, Forge Therapeutics Inc, Kyorin Pharmaceutical Co Ltd, LegoChem Biosciences Inc, Melinta Therapeutics Inc, Microbiotix Inc, Neoculi Pty Ltd, Nosopharm SAS, Oryn Therapeutics, Phico Therapeutics Ltd, Shionogi & Co Ltd, Soligenix Inc, Spero Therapeutics Inc, Syntiron LLC, Tetraphase Pharmaceuticals Inc, Vaxdyn SL, Vaxxilon AG, X4 Pharmaceuticals

Report Coverage

What to look out for in 2020

Drugs moving from early stage to mid-to-late stages and drugs to look after in 2020 are included

Pipeline Snapshot

Pipeline candidate count - Drug by phase, mechanism of action, route of administration, designation and others

Companies

31 Companies investing in Klebsiella pneumoniae Infections pipeline from discovery stage to pre-registration phase are included

Drug profiles

Over 10 details of each Klebsiella pneumoniae Infections pipeline candidate are included

Company Profiles



Business overview and contact details of all companies operating in the industry are provided

Market Developments

News, Developments and other recent industry developments are included



Contents

1. KLEBSIELLA PNEUMONIAE INFECTIONS PIPELINE MARKET INSIGHTS, 2020

- 1.1 Klebsiella pneumoniae Infections Disease Overview
- 1.2 Klebsiella pneumoniae Infections Drug Pipeline Snapshot, 2020
- 1.2.1 Klebsiella pneumoniae Infections Pipeline Drugs by Phase
- 1.2.2 Klebsiella pneumoniae Infections Pipeline Drugs by Company
- 1.2.3 Klebsiella pneumoniae Infections Pipeline Drugs by Mechanism of Action
- 1.2.4 Klebsiella pneumoniae Infections Pipeline Drugs by Route of Administration

2. KLEBSIELLA PNEUMONIAE INFECTIONS COMPANY WISE PIPELINE DETAILS

ABAC Therapeutics SA Klebsiella pneumoniae Infections Pipeline Drugs

Company Profile

Drug Candidate Details

Abgentis Ltd Klebsiella pneumoniae Infections Pipeline Drugs

Company Profile

Drug Candidate Details

AmpliPhi Biosciences Corp Klebsiella pneumoniae Infections Pipeline Drugs

Company Profile

Drug Candidate Details

Appili Therapeutics Inc Klebsiella pneumoniae Infections Pipeline Drugs

Company Profile

Drug Candidate Details

Armata Pharmaceuticals Inc Klebsiella pneumoniae Infections Pipeline Drugs

Company Profile

Drug Candidate Details

Biomx Ltd Klebsiella pneumoniae Infections Pipeline Drugs

Company Profile

Drug Candidate Details

C3J Therapeutics Inc Klebsiella pneumoniae Infections Pipeline Drugs

Company Profile

Drug Candidate Details

ContraFect Corp Klebsiella pneumoniae Infections Pipeline Drugs

Company Profile

Drug Candidate Details

Daiichi Sankyo Co Ltd Klebsiella pneumoniae Infections Pipeline Drugs

Company Profile



Drug Candidate Details

Debiopharm International SA Klebsiella pneumoniae Infections Pipeline Drugs

Company Profile

Drug Candidate Details

EnBiotix Inc Klebsiella pneumoniae Infections Pipeline Drugs

Company Profile

Drug Candidate Details

Evaxion Biotech ApS Klebsiella pneumoniae Infections Pipeline Drugs

Company Profile

Drug Candidate Details

F. Hoffmann-La Roche Ltd Klebsiella pneumoniae Infections Pipeline Drugs

Company Profile

Drug Candidate Details

Fedora Pharmaceuticals Inc Klebsiella pneumoniae Infections Pipeline Drugs

Company Profile

Drug Candidate Details

Forge Therapeutics Inc Klebsiella pneumoniae Infections Pipeline Drugs

Company Profile

Drug Candidate Details

Kyorin Pharmaceutical Co Ltd Klebsiella pneumoniae Infections Pipeline Drugs

Company Profile

Drug Candidate Details

LegoChem Biosciences Inc Klebsiella pneumoniae Infections Pipeline Drugs

Company Profile

Drug Candidate Details

Melinta Therapeutics Inc Klebsiella pneumoniae Infections Pipeline Drugs

Company Profile

Drug Candidate Details

Microbiotix Inc Klebsiella pneumoniae Infections Pipeline Drugs

Company Profile

Drug Candidate Details

Neoculi Pty Ltd Klebsiella pneumoniae Infections Pipeline Drugs

Company Profile

Drug Candidate Details

Nosopharm SAS Klebsiella pneumoniae Infections Pipeline Drugs

Company Profile

Drug Candidate Details

Oryn Therapeutics Klebsiella pneumoniae Infections Pipeline Drugs

Company Profile



Drug Candidate Details

Phico Therapeutics Ltd Klebsiella pneumoniae Infections Pipeline Drugs

Company Profile

Drug Candidate Details

Shionogi & Co Ltd Klebsiella pneumoniae Infections Pipeline Drugs

Company Profile

Drug Candidate Details

Soligenix Inc Klebsiella pneumoniae Infections Pipeline Drugs

Company Profile

Drug Candidate Details

Spero Therapeutics Inc Klebsiella pneumoniae Infections Pipeline Drugs

Company Profile

Drug Candidate Details

Syntiron LLC Klebsiella pneumoniae Infections Pipeline Drugs

Company Profile

Drug Candidate Details

Tetraphase Pharmaceuticals Inc Klebsiella pneumoniae Infections Pipeline Drugs

Company Profile

Drug Candidate Details

Vaxdyn SL Klebsiella pneumoniae Infections Pipeline Drugs

Company Profile

Drug Candidate Details

Vaxxilon AG Klebsiella pneumoniae Infections Pipeline Drugs

Company Profile

Drug Candidate Details

X4 Pharmaceuticals Klebsiella pneumoniae Infections Pipeline Drugs

Company Profile

Drug Candidate Details

3. KLEBSIELLA PNEUMONIAE INFECTIONS DRUG PIPELINE PROFILES

- 3.1 Discovery and Preclinical Drug Profiles
- 3.2 Phase 1 Drug Profiles
- 3.3 Phase 2 Drug Profiles
- 3.4 Phase 3 Drug Profiles

4. KLEBSIELLA PNEUMONIAE INFECTIONS PIPELINE NEWS AND DEVELOPMENTS



5. APPENDIX

- 5.1 Primary and Secondary Research Methodology
- 5.2 Publisher Expertize
- 5.3 Contacts



I would like to order

Product name: Klebsiella pneumoniae Infections Drug pipeline Report 2020- Current Status, Phase,

Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and

Clinical Drugs

Product link: https://marketpublishers.com/r/KF4773F0EFF9EN.html

Price: US\$ 1,699.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/KF4773F0EFF9EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below



and fax the completed form to +44 20 7900 3970